THE BLOOD FACTOR
-
Update on access to coagulation products for hemophilia A and B
by David Page, CHS National Director of Health Policy Access to a wide range of coagulation products is expanding in the provinces and territories served by...
-
Novel treatments in bleeding disorders: The European Haemophilia Consortium Review
CLICK HERE to access the June 2021 review of novel treatments in haemophilia and other bleeding disorders by the European Haemophilia Consortium.
-
Coagulation products | Current and in the pipeline
Updated charts for products in the pipeline have been uploaded on the CHS website. The CHS publishes four charts, one each for clotting factor concentrates,...
-
Fitusiran trial restarts with new controls
BRUSSELS – During the European Association for Haemophilia and Allied Disorders (EAHAD) virtual congress session on the latest clinical trial, Dr. Shauna Anderson, representing Sanofi,...
-
FDA puts uniQure’s gene therapy clinical programme, HOPE-B, on hold following submission of a safety report
December 21, 2020 – The European Haemophilia Consortium (EHC) has learned that uniQure announced that its haemophilia B gene therapy programme, including the pivotal, phase...